AstraZeneca’s COVID-19 vaccine carries a small extra risk of rare blood clots with low platelets after the first dose and no extra risk after the second, a study led and funded by the drugmaker showed on Wednesday, after worries over side-effects. The study, published in the Lancet medical journal, found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the first dose was 8.1 per million in those inoculated, AstraZeneca said. After the second dose of the vaccine, branded Vaxzevria and invented by Oxford University, the rate was 2.3 per million, comparable to that seen in unvaccinated people, the Anglo-Swedish company added. AstraZeneca’s shot has faced several setbacks, including production delays, and rare cases of severe side-effects, including TTS, which led to several countries restricting or stopping the use of the vaccine, probes by regulators, and warning labels. The European Union’s (EU) drugs regulator has been looking into …